This article was originally published in The Gray Sheet
Executive SummaryPrudential Health Plans joins a growing list of third party payers that are reimbursing for the ThinPrep Pap Test for cervical cancer screening, the company told investors at a June 9 Piper Jaffray conference in Minneapolis. The test, which sells at a list price of $475 for 40 tests, has been accepted for reimbursement by independent Blue Cross and Blue Shield health plans in New York (Empire), North Carolina, Maryland, Montana, and West Virginia (Mountain State) and by Oxford Health Plans. Pennsylvania-based Highmark Blue Cross and Blue Shield rejected a reimbursement request by Cytyc earlier this year citing a lack of evidence to demonstrate cost effectiveness of the device ("The Gray Sheet" Feb. 16, p. 9). Cytyc is considering seeking labeling to allow for screening for common sexually transmitted diseases
You may also be interested in...
The Chinese government's plan to reduce tariffs it imposed on a slew of US exports is expected to have minimal impact on the overall medtech industry. See what Ralph Ives, AdvaMed's executive VP for global strategy, said about it here.
FDA approved sNDAs from GlaxoSmithKline for diclofenac-containing Voltaren Arthritis Pain for the temporary relief of arthritis pain and from Alcon for Pataday olopatadine drops at 0.2% concentration for once-daily use temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair or dander and 0.1% for twice-daily use for the same indications plus redness relief.